Search clinical trials for: NVX-COV2373

Total 620 results

Vertex Pharmaceuticals Incorporated

Completed

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Cystic Fibrosis

Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, Canada
University Hospital, Montpellier

Recruiting

RESist Against Irritability Superiority Trial (RESIST)

Irritable Mood

France
Nicox Ophthalmics, Inc.

Completed

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Glaucoma, Open-Angle | Hypertension, Ocular

United States
Edixomed Ltd
Queen Mary University of London

Completed

Nitric Oxide Generating Gel Dressing in Patients With Diabetic Foot Ulcers (ProNOx1)

Diabetic Foot Ulcer

United Kingdom
N.M. Wulffraat
University Medical Center Groningen; Maastricht University Medical Center; Erasmus... and other collaborators

Completed

Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis (VAART)

Arthritis, Juvenile Rheumatoid

Netherlands
Forest Laboratories

Terminated

Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure

Portal Hypertension

Spain
NovaBay Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis (BACTOvation™)

Bacterial Conjunctivitis

United States
TME Pharma AG

Completed

Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model

Anemia of Chronic Disease

Netherlands
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Turtle Shell Technologies Pvt. Ltd.

Recruiting

Non-invasive Monitoring: Impact on Patient Management and Outcomes

No Specific Medical Conditions or Disease States

United States
Vertex Pharmaceuticals Incorporated

Recruiting

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease (AMPLITUDE)

Proteinuric Kidney Disease

United States, Spain, Ghana, France, United Kingdom, Belgium, Brazil, Colombia, Portugal, Canada, Puerto Rico, Netherlands
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants

Pain

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

Alpha1-Antitrypsin Deficiency

United States, Germany, Canada, Ireland, Sweden, United Kingdom
Vertex Pharmaceuticals Incorporated

Terminated

Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

Cervical Spinal Cord Injury

United States, Canada
Janssen Infectious Diseases BVBA

Completed

A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment

Hepatic Impairment

Germany, Czech Republic
Vertex Pharmaceuticals Incorporated

Completed

A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Poland, Belgium, Romania, Serbia, United States, Puerto Rico, Germany, Hungary, Russian Federation, Croatia
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Cystic Fibrosis

United States
Oregon Health and Science University
Oregon State University; Oregon Department of Corrections; CODA Inc.; Bridgeway... and other collaborators

Completed

Reducing Overdose After Release From Incarceration (ROAR)

Overdose, Drug

United States
Vertex Pharmaceuticals Incorporated

Not yet recruiting

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Cystic Fibrosis

United Kingdom, Canada, Switzerland, Australia
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

Spain, Belgium, Australia, Canada, Czechia
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1, First-in-human Study of VX-668

Alpha-1 Antitrypsin Deficiency

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1, First-in-human Study of VX-634

Alpha 1-Antitrypsin Deficiency

United States
Vertex Pharmaceuticals Incorporated

Terminated

Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

Alpha 1-Antitrypsin Deficiency

United States, Germany, Canada, Ireland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

Small Fiber Neuropathy

United States, Netherlands, Germany, Italy
Vertex Pharmaceuticals Incorporated

Completed

A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee

Osteoarthritis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Hepatitis C | Chronic Hepatitis C | HCV | CHC

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

Cystic Fibrosis

United States, Belgium, Canada, Netherlands, Germany
Vertex Pharmaceuticals Incorporated

Completed

VX-950 and Peginterferon for Hepatitis C

Hepatitis C

Germany, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Cystic Fibrosis

Canada, France, United Kingdom, Israel, Australia, Spain, Germany, Netherlands, Denmark, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Denmark, Germany, Italy, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Israel, Australia, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
TME Pharma AG

Completed

First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94

Inflammation | Anemia | Chronic Diseases

United Kingdom
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Pain

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

Renal Impairment

United States
University Hospital, Toulouse
Fondation Plan Alzheimer

Completed

Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients (VIP)

Alzheimer Disease

France
EIP Pharma Inc
Voisin Consulting, Inc.

Terminated

Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease

Huntington Disease

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

Cystic Fibrosis

United States, United Kingdom, Canada, Australia, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Cystic Fibrosis

United States, Australia, Canada, United Kingdom, Germany, Belgium, Austria, Ireland, Italy, France
Carnegie Mellon University
University of Pittsburgh

Recruiting

Game-based Pediatric Diabetes Education (DVx-T1D)

Diabetes Mellitus, Type 1 | Behavior, Health

United States
NOxy Health Products, LLC

Suspended

NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers (NTCDU) (NTCDU)

Diabetic Foot Ulcer

Israel
University of Southern California
Sponsor Name Pending

Withdrawn

New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia

United States
University of Calgary
Stem Cell Therapeutics Corp.

Unknown

Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1

Traumatic Brain Injury

Canada
Vertex Pharmaceuticals Incorporated

Approved for marketing

VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)

Cystic Fibrosis

Search clinical trials for: NVX-COV2373

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations